Cytostatic Benzylidene-isophthaloylhydazides With Diminished Neurotoxicity

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Organic Synthesis

Background:

• Benzylidene-isophthaloylhydrazides are identified as promising scaffolds for anticancer drug design due to their functional groups.
• These compounds offer potential for thiol alkylation, hydrogen bonding, and van der Waals interactions.

Purpose of the Study:

• To synthesize novel benzylidene-isophthaloylhydrazide derivatives (1a-o).
• To evaluate their anticancer potency, tumor selectivity, neurotoxicity, and drug-like properties.
• To establish structure-activity relationships for optimized anticancer drug candidates.

Main Methods:

• Synthesis of compounds 1a-o via condensation reactions.
• Cytotoxicity assessment using MTT assays on oral cancer cells, normal oral cells, and neuronal cells.
• Evaluation of tumor selectivity (SI) and anticancer/neurotoxicity ratio (RAN).
• Cell-cycle analysis, apoptosis induction studies (Western blotting, flow cytometry), and computational analysis (torsion angles, QSAR).

Main Results:

• Compounds demonstrated selective cytotoxicity towards neoplastic cells.
• Compound 1h exhibited superior tumor specificity (SI >59.5) and minimal neurotoxicity compared to standard drugs.
• Compounds 1d, 1f, and 1h showed high RAN values, indicating reduced neurotoxicity.
• Compound 1h induced S-phase arrest and apoptosis, with caspase-3 activation.
• Dimeric analogs were more potent; higher torsion angles correlated with enhanced activity.
• Favorable Absorption, Distribution, Metabolism, and Excretion (ADME) properties were observed.

Conclusions:

• Benzylidene-isophthaloylhydrazides, especially compound 1h, are promising antineoplastic agents.
• Compound 1h offers significant tumor selectivity and low neurotoxicity with favorable ADME properties.
• These findings support further optimization and preclinical development of these novel anticancer agents.